Skip to main content
. 2020 Jan 1;11(4):826–836. doi: 10.7150/jca.36203

Figure 1.

Figure 1

The plasmin is produced when S100A10 (P11) combines to plasminogen and (or) plasminogen activator, and the plasmin can promote the transformation of pro-MMPs to MMPs, such as MMP-2 and MMP-9. Both the plasmin and MMPs collectively promote the tumor progression, including invasion and metastasis. Ras oncogene activates S100A10 expression which activates plasminogen to generate plasmin, and upregulates expression level of plasmin, MMP-2 and MMP-9, which depends on S100A10. DLC1 can competitively combine to S100A10 with annexinA2 (P36), resulting in the separation of P11 and P36 and consequent the ubiquitination degradation of P11, which inhibits tumor progression. S100A10 is associated with depression-like symptoms through affecting the location of 5-HT1B receptor on the cell surface. RAS can increase the transcription of S100A10 through its signaling pathway, resulting in increased expression of S100A10 and consequent generation of plasmin.